← Back
Data updated: Jun 28, 2026
ABLYNX NV
Biotech Pharmaceuticals
ABLYNX NV is a biotechnology company with 1 FDA-approved products.
2019
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
FDA Novel Drug Designations
(2019) 1 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 1 novel approval →
2019 CABLIVI (CAPLACIZUMAB-YHDP) First-in-Class · Orphan · Priority Review · Fast Track
ABLYNX NV's Key Drugs
ABLYNX NV's core commercial portfolio centers on CABLIVI — its most strategically important drugs approved in the last 15 years.
ABLYNX NV's Recent FDA Approvals
New NDA/BLA approvals for ABLYNX NV over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ABLYNX NV's Therapeutic Areas
Disease areas where ABLYNX NV has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ABLYNX NV Pipeline Snapshot
Active clinical trials for ABLYNX NV across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CABLIVI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2019-02-06
- Latest
- 2025-12-23
- Applications
- 1